Dr. Zachary Crees joins the Department ...

Dr. Zachary D Crees, M.D.

Claim this profile

Washington University School of Medicine

Studies Multiple Myeloma
Studies Sickle Cell Disease
8 reported clinical trials
15 drugs studied

Area of expertise

1Multiple Myeloma
Zachary D Crees, M.D. has run 4 trials for Multiple Myeloma.
2Sickle Cell Disease
Zachary D Crees, M.D. has run 1 trial for Sickle Cell Disease. Some of their research focus areas include:
Sβ0 genotype positive
hemoglobin SS positive

Affiliated Hospitals

Image of trial facility.
Washington University School Of Medicine

Clinical Trials Zachary D Crees, M.D. is currently running

Image of trial facility.

Mosunetuzumab

for Aggressive B-Cell Lymphoma

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Recruiting2 awards Phase 1
Image of trial facility.

CAR-T Therapy

for Multiple Myeloma

Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
Recruiting1 award Phase 1

More about Zachary D Crees, M.D.

Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Zachary D Crees, M.D. has experience with
  • Motixafortide
  • Leukapheresis
  • Natalizumab
  • Flotetuzumab
  • MGD006
  • Donor Lymphocyte Infusion

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Zachary D Crees, M.D. specialize in?
Is Zachary D Crees, M.D. currently recruiting for clinical trials?
Are there any treatments that Zachary D Crees, M.D. has studied deeply?
What is the best way to schedule an appointment with Zachary D Crees, M.D.?
What is the office address of Zachary D Crees, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security